Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

NCT05304585 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT05304585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Recruiting
Start date
August 4, 2022
Completion date
June 30, 2030
Enrollment
205 (estimated)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

embryonal rhabdomyosarcoma, fusion-negative alveolar rhabdomyosarcoma, spindle cell/sclerosing rhabdomyosarcoma